Nadine Mueller-Calleja, Kristin Grunz, Thanh Son Nguyen, Jens Posma, Denise Pedrosa, Myriam Meineck, Anne Hollerbach, Johannes Braun, Sabine Muth, Hansjoerg Schild, Kathrin Saar, Norbert Hübner, Sriram Krishnaswamy, Jennifer Royce, Luc Teyton, Niels A Lemmermann, Julia Weinmann-Menke, Karl J Lackner, Wolfram Ruf
Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) are a major cause for acquired thrombophilia, but specific interventions preventing autoimmune aPL development are an unmet clinical need. While autoimmune aPL cross-react with various coagulation regulatory proteins, lipid-reactive and COVID-19 patient-derived aPL recognize the endo-lysosomal phospholipid lysobisphosphatidic acid (LBPA) presented by the cell surface expressed endothelial protein C receptor (EPCR). This specific recognition leads to complement-mediated activation of tissue factor (TF) dependent proinflammatory signaling and thrombosis...
December 24, 2023: Blood